- Home
- RARE vs VC Comparison
RARE vs VC Comparison
Compare RARE & VC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- VC
- Stock Information
- Founded
- RARE 2010
- VC 2000
- Country
- RARE United States
- VC United States
- Employees
- RARE N/A
- VC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- VC Auto Parts:O.E.M.
- Sector
- RARE Health Care
- VC Consumer Discretionary
- Exchange
- RARE Nasdaq
- VC Nasdaq
- Market Cap
- RARE 2.6B
- VC 3.0B
- IPO Year
- RARE 2014
- VC 2000
- Fundamental
- Price
- RARE $29.96
- VC $123.64
- Analyst Decision
- RARE Strong Buy
- VC Buy
- Analyst Count
- RARE 14
- VC 12
- Target Price
- RARE $86.64
- VC $116.10
- AVG Volume (30 Days)
- RARE 1.4M
- VC 286.6K
- Earning Date
- RARE 08-05-2025
- VC 10-23-2025
- Dividend Yield
- RARE N/A
- VC 0.89%
- EPS Growth
- RARE N/A
- VC N/A
- EPS
- RARE N/A
- VC 10.51
- Revenue
- RARE $610,159,000.00
- VC $3,822,000,000.00
- Revenue This Year
- RARE $19.72
- VC $0.78
- Revenue Next Year
- RARE $23.29
- VC $3.52
- P/E Ratio
- RARE N/A
- VC $11.79
- Revenue Growth
- RARE 26.77
- VC N/A
- 52 Week Low
- RARE $25.81
- VC $65.10
- 52 Week High
- RARE $60.37
- VC $128.32
- Technical
- Relative Strength Index (RSI)
- RARE 53.11
- VC 69.57
- Support Level
- RARE $29.04
- VC $125.02
- Resistance Level
- RARE $30.61
- VC $128.32
- Average True Range (ATR)
- RARE 0.80
- VC 3.05
- MACD
- RARE 0.31
- VC 0.17
- Stochastic Oscillator
- RARE 79.81
- VC 84.33
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About VC Visteon Corporation
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.